Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Topical PAT-001 in Congenital Ichthyosis
NCT02864082Phase 2Completed
- Sponsor
- Patagonia Pharmaceuticals
- Start
- Mar 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TMB-001 in congenital ichthyosis, sponsored by Patagonia Pharmaceuticals. Started Mar 2017; status: completed.
02
Drugs
TMB-001
03
Conditions
congenital ichthyosis
Beyond the preview
Go deeper on NCT02864082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02864082.